<unk>  (trade name Takecab) is a first-in-class potassium-competitive acid blocker. It was approved in the Japanese market in February 2015.<unk>  is used in form of the fumarate for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori.
Vonoprazan
Flutoprazepam
Cyprazepam
Medazepam
Icatibant
Cinolazepam
Fluparoxan
Adatanserin